4056-78-4

Basic information

• Product Name: NORCAMPHORICACID
• Synonyms: NORCAMPHORICACID;1,3-Cyclopentanedicarboxylic acid;Cyclopentane-1,3-dicarboxylic acid
• CAS NO: 4056-78-4
• Molecular Formula: C₇H₁₀O₄
• Molecular Weight: 158.15
• Mol File: 4056-78-4.mol

Chemical Properties

• Melting Point: 121.5 °C
• Boiling Point: 320.7°Cat760mmHg
• Flash Point: 161.9°C
• Appearance: /
• Density: 1.396g/cm³
• Vapor Pressure: 6.51E-05mmHg at 25°C
• Refractive Index: 1.535
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.23±0.40(Predicted)
• CAS DataBase Reference: NORCAMPHORICACID(CAS DataBase Reference)
• NIST Chemistry Reference: NORCAMPHORICACID(4056-78-4)
• EPA Substance Registry System: NORCAMPHORICACID(4056-78-4)

Safety Data

• Hazardous Substances Data: 4056-78-4(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
NORCAMPHORICACID is used as a research compound for the study of ruthenium-catalyzed oxidation of alkenes and monoenic fatty acids. This application is significant as it contributes to the understanding of chemical reactions and the development of new synthetic methods in the field of organic chemistry.
Used in Pharmaceutical Industry:
NORCAMPHORICACID can be utilized as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a valuable building block for the development of new drugs with potential therapeutic applications.
Used in Material Science:
Due to its chemical properties, NORCAMPHORICACID may also find applications in the development of new materials with specific properties, such as polymers with tailored characteristics for use in various industries, including automotive, aerospace, and electronics.

InChI:InChI=1/C7H10O4/c8-6(9)4-1-2-5(3-4)7(10)11/h4-5H,1-3H2,(H,8,9)(H,10,11)/t4-,5+

Upstream product

• 498-66-8 norborn-2-ene 
• 18084-03-2 2-ethynylbicyclo[2.2.1]heptan-2-ol 
• 497-38-1 Norbornan-2-on 
• 71720-43-9 (Bicyclo<2.2.1>hept-2-en-2-yl)-1-ethanon 
• 87238-75-3 tricyclo<5.2.1.0².⁶>dec-2(6)-ene 

Downstream Products

• 2435-36-1 cyclopentane?1,3?dimethyl formate 
• 2453-00-1 1,3-dimethylcyclopentane 
• 1610729-44-6 (S,S)-dibenzyl cyclopentyl 1,3-dicarboxylate 
• 36010-89-6 (S,S)-cyclopentyl 1,3-dicarboxylic acid 
• 62959-20-0 1,3-cyclopentanedicarboxamide 
• 1341037-89-5 2-(tert-butoxycarbonyl)-2-azaspiro[4.4]nonane-7-carboxylic acid 
• 1201186-85-7 methyl 4-((tert-butoxycarbonyl)amino)bicyclo[2.2.1]heptane-1-carboxylate 
• 1252672-35-7 4-(benzyloxycarbonylamino)bicyclo[2.2.1]heptane-1-carboxylic acid methyl ester 
• 15544-51-1 bicyclo<2.2.1>heptane-1,4-dicarboxylic acid 
• 1403865-38-2 benzyl 4-hydroxybicyclo[2.2.1]heptan-1-ylcarbamate 
• 737693-57-1 4-aminobicyclo[2.2.1]heptane-1-carboxylic acid 
• 1252672-36-8 4-(benzyloxycarbonylamino)bicyclo[2.2.1]heptane-1-carboxylic acid 
• 15448-77-8 4-carbomethoxybicyclo<2.2.1>heptane-1-carboxylic acid 
• 15448-76-7 dimethyl bicyclo<2.2.1>heptane-1,4-dicarboxylate 

Relevant articles and documents

Polycyclic amide derivative as CDK9 inhibitor, and preparation method and application thereof

The invention belongs to the technical field of polycyclic amide derivatives, and particularly relates to a polycyclic amide derivative as a CDK9 inhibitor, and a preparation method and application thereof. The polycyclic amide derivative shows excellent CDK9 enzyme inhibitory activity, and can be used for preparing drugs for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors, such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia and follicular lymphoma, including breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.

Liquid-phase catalytic oxidation of C6-C7 cycloolefins into carboxylic acids in a pseudohomogeneous system

Liquid-phase oxidation of cyclohexene, methylcyclohexene isomers, and norbornene with a 30% solution of hydrogen peroxide in a pseudohomogeneous system involving highly dispersed compounds of Group-VIb and -VIIIb metals supported by nanosize carbon particles was studied.

Design, synthesis, radiolabeling, and in vitro and in vivo evaluation of bridgehead iodinated analogues of N -{2-[4-(2-methoxyphenyl)piperazin-1-yl] ethyl}- N -(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) as potential SPECT ligands for the 5-HT1A receptor

Here we describe the design, synthesis, and pharmacological profile of 5-HT1A receptor ligands related to 1 (WAY-100635). The cyclohexyl moiety in 1 and its O-desmethylated analogue 3 were replaced by the bridgehead iodinated bridge-fused rings: adamantyl, cubyl, bicyclo[2.2.2]octyl, or bicyclo[2.2.1]heptyl. All analogues displayed a (sub)nanomolar affinity for the 5-HT1A receptor in vitro. Compounds 6b and 7b appeared to be selective for this receptor over other relevant receptors and could easily be iodinated with radioactive iodine-123. In humane hepatocytes, [ 123I]6b showed a low propensity for amide hydrolysis and a stable carbon-iodine bond. The biodistribution of [123I]6b and [ 123I]7b in rats revealed that the carbon-iodine bond was also stable in vivo. Unfortunately, the brain uptake and the specificity for both radioligands were significantly lower than those of the parent molecule 1. In conclusion, the designed tracers are not suitable for SPECT imaging.

Catalytic oxidative cleavage of olefins by RuO4 organic solvent-free under ultrasonic irradiation

All the works reported about oxidative cleavage of olefins by the RuCl3/NaIO4 catalytic system have been performed in biphasic water/organic solvent(s). The first organic solvent-free oxidation of C{double bond, long}C double bond by 2% RuCl3/4.1 equiv NaIO4/H2O is described here using both the emulsifier Aliquat 336 and 20 kHz ultrasonic irradiation.

HETEROBICYCLIC METALLOPROTEASE INHIBITORS

The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP- 13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP- 13 inhibitors.

Ruthenium catalysed oxidation without CCl4 of oleic acid, other monoenic fatty acids and alkenes

Ruthenium catalysed oxidation of alkenes and monoenic fatty acids is reported. The study of the influence of cosolvents (H2O/MeCN/X) shows that toxic CCl4 initially used in the Sharpless system (H 2O/MeCN/CCl4) can be avoided and demonstrates that the oxidative cleavage of CC bond could be accomplished in good yields with H 2O/MeCN/AcOEt solvent system in a ratio 3/2/2, respectively.

Synthesis of Bridgehead-Bridgehead Substituted Bicycloalkanes

A convenient synthetic route to several bicycloalkanes bearing substitution at both bridgehead positions is described.The two-step procedure, which involves alkylation of the monoenolates of readily available cyclohexane diesters with 1,2-dihaloethane followed by a base-inducted cyclization of the derived haloethylated product, was successfully applied to the synthesis of dimethyl bicyclooctane-1,4-dicarboxylate, dimethyl bicycloheptane-1,4-dicarboxylate and dimethyl bicyclooctane-1,5-dicarboxylate.Additionally, it was found that the two latter diesters could be obtained in quite acceptable yields in a one-pot procedure through their corresponding cyclohexyl bisenolate precursors.

1,1-Alkanediol dicarboxylate linked antibacterial agents

Useful antibacterial agents in which a penicillin and/or a beta-lactamase inhibitor are linked via 1,1-alkanediol dicarboxylates are of the formula STR1 where A is the residue of certain dicarboxyic acids, R3 is H or (C1 -C3), n is zero or 1 such that when n is zero R is P or B and R1 is the residue of certain esters, H or a salt thereof; and when n is 1, one of R and R1 is P and the other is B, and P is STR2 where R2 is H or certain acyl groups, and B is the residue of a beta-lactamase inhibiting carboxylic acid; a method for their use, pharmaceutical compositions thereof and intermediates useful in their production.